Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, dedicated to the discovery and development of oral recombinant protein vaccines. The company’s innovative vaccine platform focuses on creating oral tablet vaccines for various infectious diseases, including norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus. Vaxart’s norovirus vaccine has completed Phase I clinical trials, while its seasonal influenza vaccine is currently in Phase II trials. Additionally, Vaxart is exploring therapeutic immune-oncology vaccines for cervical cancer and HPV-related dysplasia. The company also collaborates with Janssen Vaccines & Prevention B.V. to assess its oral vaccine technology for the universal influenza vaccine program. Founded in 2004, Vaxart has established a strong patent portfolio around its novel vaccination technology, aiming to develop rapid and efficient solutions to combat infectious diseases.
Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates: laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the United States. through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that provides up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage development programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.